| "Zymobacterium oroticum" Wachsman and Barker 1954| ATCC 13619| ATCC 25750| BCRC 14529| Clostridium oroticum| Clostridium oroticum (Wachsman and Barker 1954) Cato et al. 1968 (Approved Lists 1980)| DSM 1287| Faecalicatena orotica| Faecalicatena orotica (Wachsman and Barker 1954) Sakamoto et al. 2017| JCM 1429| LMG 3286| LMG:3286| NCCB 73016| NCIMB 10650| VPI 0565| Zymobacterium oroticum
Gut microbiota: Faecalicatena orotica is part of the human gut microbiota, meaning it inhabits the gastrointestinal tract. The gut microbiota plays a crucial role in human health, influencing various physiological processes such as digestion, metabolism, immune function, and protection against pathogens.
Orotic acid metabolism: Faecalicatena orotica has a unique ability to metabolize orotic acid, which is a precursor in the biosynthesis of pyrimidine nucleotides. This metabolic capability may have implications for the host's overall metabolism and the balance of nucleotide pools in the gut environment.
Associations with health conditions: While specific health impacts of Faecalicatena orotica are not well-established, alterations in the composition and function of the gut microbiota have been implicated in various health conditions, including inflammatory bowel diseases (IBD), obesity, metabolic syndrome, and colorectal cancer. Changes in the abundance or activity of Faecalicatena orotica in the gut microbiota may potentially influence the development or progression of these conditions, although direct evidence is lacking.
Probiotic potential: Given its presence in the gut microbiota and its unique metabolic capabilities, Faecalicatena orotica may have potential applications as a probiotic or in microbial-based therapies aimed at modulating gut microbiota composition and function. However, further research is needed to assess its safety, efficacy, and potential benefits in human health.
Research gaps: Despite its discovery, Faecalicatena orotica remains relatively understudied compared to other members of the gut microbiota. More research is needed to elucidate its role in gut ecology, its interactions with the host, and its potential contributions to health and disease.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab Low and High are calculated using the formula that most labs use: Mean - 2 Standard Deviation to Mean + 2 Standard Deviation
Lab | KM Low | KM Percentile Low | KM High | KM Percentile High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High |
---|---|---|---|---|---|---|---|---|---|---|---|
* | 159 | 9.1 %ile | 900 | 81.8 %ile | 0 | 970 | 433.7 | 283 | 273.8 | 159 | 900 |
thryve | 21 | 12.1 %ile | 407 | 90.3 %ile | 0 | 4166 | 407.7 | 63 | 1917.4 | 0 | 385 |
Low Boundary | High Boundary | Low Boundary %age | High Boundary %age | Lab Samples |
---|
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
custom | 1.695 % | 0.065 % | % | 1.0 | 59 |
Microba1 | 100 % | 0.09 % | % | 1.0 | 1 |
SequentiaBiotech | 19.444 % | 0.034 % | 0.021 % | 7.0 | 36 |
Thryve | 66.739 % | 0.048 % | 0.214 % | 921.0 | 1380 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.